Novartis Venture Fund
VC Fund
Basel, Switzerland
Novartis Venture Fund is a VC fund in Basel focused on Biotechnology and Health Care. Novartis Venture Fund's primary focus is on the development of novel therapeutics and platforms. They balance the therapeutic focus with investments in medical devices, diagnostics, or drug delivery systems. In their investments, they look for unmet needs and clinical impact, novel proprietary science, an understanding of mechanism, managementand board experience, and capital efficiency in the program.Novartis Venture Fund prefers to have their initial investment at the early stage to build the company and follow with additional investment in pace with the company's progress. Their approach involves larger focused investments, with anticipation of total investments up to USD 30 to 50 million per company over its life, but it can be as little as 100,000 USD to get started. They plan to increase their activities to lead or co-lead deals further and remain open to participating in larger syndicates.
- Total investments:
- 219
- Last investment:
- Lead investor:
- 26%
- Fund size:
- $200M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Novartis Venture Fund invests in
Stages Novartis Venture Fund invests in
Countries Novartis Venture Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.1M–$81M
- Series B
- $11M–$120M
- Series C
- $9M–$75M
Investment Focus
Industry
- Biotechnology 112 (51%)
- Health Care 74 (34%)
- Therapeutics 47 (21%)
- Medical 34 (16%)
- Pharmaceutical 30 (14%)
Stage
- Series B 60 (27%)
- Series A 58 (26%)
- Series C 32 (15%)
- Funding Round 13 (6%)
- Series D 11 (5%)
Country
- United States 81 (37%)
- Switzerland 13 (6%)
- United Kingdom 11 (5%)
- France 3 (1%)
- Germany 3 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Aaron Nelson
Principal & Managing Director
|
Principal & Managing Director | Total investments: 1 | Find email | |
Anja König
Global Head Novartis Venture Fund
|
Global Head Novartis Venture Fund | Total investments: 13 | Find email | |
Bart Dzikowski
Managing Director, Head of Transactions & Legal
|
Managing Director, Head of Transactions & Legal | Total investments: 0 | Find email | |
Florent Gros
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Florent Gros
Managing Director
|
Managing Director | Total investments: 12 | Find email | |
| See all 11 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $67.4M / Series D / Jul 07, 2026 | |
Sidewinder Therapeutics
|
Sidewinder Therapeutics develops bispecific antibody-drug conjugates (ADCs) aimed at treating solid tumors. Their mission is to create life-saving therapies through precision therapeutics. | $137M / Series B / Apr 08, 2026 | |
EpiBiologics
|
EpiBiologics develops first-in-class antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology. | $107M / Series B / Jan 08, 2026 | |
FoRx Therapeutics
|
FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $50M / Series A / Dec 18, 2025 | |
Protego Biopharma
|
Protego Biopharma develops therapeutics based on the clear human genetic link, excellent human safety profile, proof-of-principle efficacy. The company was founded in 2011 and is headquartered in San Diego, California. | $130M / Series B / Dec 01, 2025 | |
Artios Pharma
|
Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M / Series D / Nov 17, 2025 | |
NRG Therapeutics
|
NRG Therapeutics is a drug discovery company focussed on therapeutic approaches that will restore mitochondrial function and slow or halt the progression of neurodegenerative diseases such as Parkinson’s disease, Alzheimer’s disease and motor neurone disease. Founded in 2018 by a team of experienced biotech and pharmaceutical industryprofessionals, with a background in neuroscience drug discovery, NRG Therapeutics will initially focus on the discovery and development of brain penetrant mitochondrial permeability transition pore inhibitors for the treatment of Parkinson’s disease. | $67.8M / Series B / Sep 08, 2025 | |
Splice Bio
|
Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted. | $135M / Series B / Jun 11, 2025 | |
|
FoRx Therapeutics
|
FoRx Therapeutics is a recently incorporated privately-held company aiming to develop first-in-class compounds for cancer treatment. FoRx focuses on drugging key molecular targets involved in DNA replication stress, as a new approach towards the development of targeted anticancer drugs. | $48.6M / Series A / Jun 01, 2025 | |
|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M / Series D / May 06, 2025 | |
| See all 219 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Novartis Venture Fund invest in?
Novartis Venture Fund invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 219 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Novartis Venture Fund's check size?
Novartis Venture Fund typically joins rounds of $5.1M–$81M at Series A, $11M–$120M at Series B and $9M–$75M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Novartis Venture Fund participates in.
How do I contact Novartis Venture Fund?
Public channels for Novartis Venture Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Novartis Venture Fund?
The team at Novartis Venture Fund includes Aaron Nelson (Principal & Managing Director), Anja König (Global Head Novartis Venture Fund) and Bart Dzikowski (Managing Director, Head of Transactions & Legal), among 11 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
